EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 191 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $711,000 | -83.7% | 9,400 | -83.0% | 0.02% | -77.3% |
| Q2 2017 | $4,370,000 | -44.1% | 55,400 | -41.3% | 0.07% | -44.5% |
| Q1 2017 | $7,821,000 | +257.3% | 94,300 | +241.7% | 0.12% | +116.4% |
| Q4 2016 | $2,189,000 | +194.6% | 27,600 | +200.0% | 0.06% | -50.9% |
| Q2 2015 | $743,000 | – | 9,200 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |